Minnesota Multidisciplinary Vasculitis Program

The Minnesota Multidisciplinary Vasculitis Program (M2VP) enrolls the 200th adult patient and 1st pediatric patient into the registry!

October 2021

m2vp-group-img

Front Row L to R: S. Thaker, S. Reule, M. Rheault, H. Boyer, C. Fanola, D. Pearson, H. Muster
Back Row L to R: P. Nachman, S. Rajala, L. Ghazi, M. Beard, P. Fazeli, K. Woerner, D. Mueller, M. Pritzker, P. Ardnt

Mission

To provide patients with systemic inflammatory disease or vasculitis with cutting-edge, individualized, comprehensive and integrated multidisciplinary care and access to clinical trials.

Covered Diseases

  • Systemic vasculitis:
    • Small vessel vasculitis (ANCA-vasculitis, Anti-GBM disease, IgA Vasculitis)
    • Medium vessel vasculitis 
    • Large vessel vasculitis
  • Systemic Lupus Erythematosus

Goals

  • Provide patients with complex systemic diseases with multidisciplinary care which is organized, streamlined and efficient.
  • Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
  • Provide patients with access to cutting-edge clinical trials.
  • Facilitate translational research.
  • Provide a venue for health care providers training in the care of patients with complex systemic diseases.
     

Multidisciplinary Team

Cardiology

Dermatology

Nephrology

Otolaryngology (ENT)

Pulmonary

Rheumatology

Clinical & Translational Research Team

Ongoing Clinical Trials

ANCA Vasculitis

Coming soon!

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

 

Phase 3 Trial

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)

Principal Investigator

Surabhi Thakar, MD

Co-Investigators

Patrick Nachman, M
Katti Woerner, MD

Study Coordinator

Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL